engaging the human subject in limited exercise training for a period of time sufficient to increase sodium excretion levels in the human subject.

Please add Claim 2:

--2. (New) The method of Claim 1, wherein said method further comprises the step of testing the sodium excretion levels of the human subject following the period of time sufficient to increase sodium excretion levels.--

## REMARKS

Claim 1 is pending and Claim 1 has been rejected. In this Response, Claim 1 has been amended. Claim 2 has been added and support for Claim 2 may be found throughout the specification (e.g., pages 6 and 7). No new matter has been added.

Regarding the Information Disclosure Statement, Applicants thank the Examiner for completing citation "AM" in the Information Disclosure Statement filed on January 30, 2002.

Claim 1 has been rejected under 35 U.S.C. 112, first paragraph, as not enabled. The Examiner has taken the position that the specification does not provide enablement for methods of increasing sodium excretion levels in any type of hypertensive subject comprising identifying an II genotype for an angiotensin converting enzyme gene prior to engaging the subject in limited exercise training. However, the Examiner has admitted that the specification does provide enablement for "methods of increasing sodium excretion levels in a hypertensive human subject comprising identifying a hypertensive human subject having the human angiotensin converting enzyme gene II genotype exemplified in the specification and engaging the subject in limited exercise